Get the Stockscreener App
4.67
0.64%
-0.03
After Hours:
4.71
0.04
+0.86%
Xeris Biopharma Holdings Inc stock is traded at $4.67, with a volume of 3.02M.
It is down -0.64% in the last 24 hours and down -5.47% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$4.70
Open:
$4.71
24h Volume:
3.02M
Relative Volume:
1.10
Market Cap:
$728.71M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-11.12
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
+0.65%
1M Performance:
-5.47%
6M Performance:
+37.76%
1Y Performance:
+107.56%
1-Day Range:
$4.65
$4.90
1-Week Range:
$4.55
$4.90
52-Week Range:
$2.03
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
4.67 | 728.71M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - MarketScreener
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors By Investing.com - Investing.com South Africa
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set - marketscreener.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - mx.advfn.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation a - GuruFocus
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million - marketscreener.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc. - Defense World
XERS: Key Highlights from Analyst and Investor Day | XERS Stock News - GuruFocus
ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $273,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Bank of America Corp DE Sells 17,544 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Deutsche Bank AG Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Cut to “Hold” at Wall Street Zen - Defense World
Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than 18.7% - Stocksregister
Jane Street Group LLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Announces Details for Analyst & Investor Day - Business Wire
Balyasny Asset Management L.P. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | User | poteaudailynews.com - FinancialContent
The Manufacturers Life Insurance Company Lowers Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma Q2 Earnings - Defense World
Voya Investment Management LLC Reduces Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Raymond James Financial Inc. Purchases New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Hsbc Holdings PLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Raised by Price T Rowe Associates Inc. MD - Defense World
Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Consensus Target Price from Analysts - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):